Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen

Rapport Therapeutics (NASDAQ:RAPP) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other research analysts have also issued reports about the company. BTIG Research reiterated a “buy” rating and issued a $47.00 price objective on shares of Rapport Therapeutics in a research report on Monday, December 8th. The Goldman Sachs Group reissued a “buy” rating on shares of Rapport Therapeutics in a report on Friday, December 19th. Wells Fargo & Company assumed coverage on shares of Rapport Therapeutics in a research report on Monday, February 2nd. They set an “overweight” rating and a $43.00 price target for the company. Citizens Jmp raised their price objective on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Finally, HC Wainwright lifted their target price on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Rapport Therapeutics Price Performance

Shares of RAPP opened at $27.09 on Friday. The company has a market capitalization of $1.29 billion, a P/E ratio of -10.00 and a beta of 1.63. Rapport Therapeutics has a one year low of $6.43 and a one year high of $42.27. The business’s 50 day simple moving average is $28.40 and its 200-day simple moving average is $24.56.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06. On average, sell-side analysts anticipate that Rapport Therapeutics will post -3.65 EPS for the current fiscal year.

Insider Activity at Rapport Therapeutics

In related news, insider Krishnaswamy Yeleswaram sold 2,840 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a total transaction of $85,342.00. Following the transaction, the insider owned 296,991 shares of the company’s stock, valued at $8,924,579.55. This trade represents a 0.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Bredt sold 8,500 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $26.84, for a total transaction of $228,140.00. Following the transaction, the insider owned 395,575 shares of the company’s stock, valued at approximately $10,617,233. This represents a 2.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 67,655 shares of company stock worth $1,863,705 in the last ninety days. Company insiders own 13.57% of the company’s stock.

Institutional Trading of Rapport Therapeutics

A number of large investors have recently made changes to their positions in RAPP. Russell Investments Group Ltd. acquired a new stake in Rapport Therapeutics during the 3rd quarter worth $43,000. Strs Ohio grew its stake in Rapport Therapeutics by 23.5% in the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after acquiring an additional 400 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Rapport Therapeutics by 64.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after acquiring an additional 905 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after purchasing an additional 4,582 shares during the period. Finally, Creative Planning acquired a new stake in shares of Rapport Therapeutics during the second quarter worth about $121,000.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.